title: [Prevalence of antiparkinsonian treatment complications: a systematic review and estimation of projections].
abstract: BACKGROUND
  The development of Parkinson's disease (PD) presents different complications deriving from the disease itself, but also from its treatment. The appearance of side effects with the use of antiparkinsonian drugs is common and their management is complicated, which makes it necessary to determine the epidemiological impact of these problems related with antiparkinsonian medication.
  
  
  OBJECTIVE
  To estimate the prevalence of the side effects of the treatment for the motor symptoms of PD and the possible long-term impact.
  
  
  METHODS
  A systematic review was performed in the biomedical databases since the year 2004; the most relevant studies were selected and the frequencies of the most common side effects were identified. The data thus obtained were projected in order to estimate their impact in the long term.
  
  
  RESULTS
  Altogether 218 studies were identified, of which 24 were selected for the review. Data were obtained for 20 types of complications deriving from the antiparkinsonian treatment, including heart problems, oedemas and neuropsychiatric symptoms.
  
  
  CONCLUSIONS
  The estimations performed indicate that the number of patients with PD and therefore the prevalence of the side effects of antiparkinsonian treatments may well double by the year 2050.
authors.affiliation: Oficina de Farmacia Consuelo M. Sanchis Gaya, Zaragoza, Espana.
authors.forename: Daniel
authors.initials: D
authors.lastname: Fernández-Sanchis
authors.forename: Alberto Frutos
authors.initials: AF
authors.lastname: Frutos Pérez-Surio
authors.forename: Luis J
authors.initials: LJ
authors.lastname: López del Val
mesh_terms: D000058:Accidental Falls / Q000706:statistics & numerical data; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000139:chemically induced / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology; D018680:Cholinergic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D005221:Fatigue / Q000139:chemically induced / Q000453:epidemiology; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced / Q000453:epidemiology; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic; D064887:Observational Studies as Topic; D020734:Parkinsonian Disorders / Q000188:drug therapy; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic
chemical_list: D000978:Antiparkinson Agents; D018680:Cholinergic Antagonists; D018491:Dopamine Agonists